Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 96.91M | 97.10M | 103.35M | 104.04M | 89.06M |
Gross Profit | 33.30M | 33.10M | 38.10M | 39.81M | 37.16M |
EBITDA | 15.70M | 15.77M | 16.12M | 26.88M | 23.99M |
Net Income | 10.84M | 11.63M | 6.24M | 20.95M | 19.05M |
Balance Sheet | |||||
Total Assets | 186.24M | 171.92M | 163.58M | 136.86M | 106.05M |
Cash, Cash Equivalents and Short-Term Investments | 15.96M | 16.93M | 26.74M | 8.15M | 7.19M |
Total Debt | 7.95M | 7.33M | 6.81M | 5.18M | 3.22M |
Total Liabilities | 27.26M | 25.08M | 24.90M | 30.05M | 21.31M |
Stockholders Equity | 158.98M | 146.33M | 138.12M | 106.81M | 84.74M |
Cash Flow | |||||
Free Cash Flow | 14.50M | -2.41M | -11.86M | -904.89K | -10.79M |
Operating Cash Flow | 14.64M | 2.28M | -9.16M | -54.66K | 5.33M |
Investing Cash Flow | -20.42M | -12.46M | -8.62M | -833.82K | -16.09M |
Financing Cash Flow | 6.21M | 706.13K | 37.25M | 1.86M | 1.71M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $12.76M | 1.26 | 5.90% | ― | -4.99% | -19.11% | |
52 Neutral | 13.20M | -0.77 | -89.16% | ― | -19.32% | 44.73% | |
51 Neutral | 25.03M | -2.79 | -11.43% | ― | -0.24% | 50.45% | |
49 Neutral | 19.77M | -0.34 | -364.88% | ― | -12.24% | -427.45% | |
44 Neutral | 8.86M | -0.55 | 6022.04% | ― | -38.79% | 58.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 15, 2025, Meihua International Medical Technologies Co., Ltd. announced significant changes in its leadership team, with the resignation of CEO Xin Wang, CFO Lianzhang Zhao, and board member Huijuan Zhao, all citing personal reasons. The company appointed Leyi Lee as the new CEO, Shilong Liao as the new CFO, and Anna Colin as an independent director, signaling a strategic shift in leadership. These appointments are expected to bring new perspectives and expertise to the company, potentially impacting its strategic direction and market positioning.